Tarlatamab is designed to help the body’s immune cells find, attach to, and attack cancer cells.

Learn more about Amgen’s commitment to
Diversity, Equity, and Inclusion
in clinical research

Who is able to join this clinical trial?

Patients who are 18 years or older

Small-cell lung cancer (SCLC) diagnosis was confirmed by tumor sample under a microscope

Small-cell lung cancer (SCLC) is only in one lung, or one lung and nearby lymph nodes

Ongoing response or no progression after chemoradiation

Participants must also meet additional eligibility criteria.

Click to download and print a description of the trial to bring to your doctor.
phone graphic

Where can I get more information?

To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.

AmgenMedInfo.com

866-572-6436

Monday - Friday 8am to 8pm (ET)

Contact Amgen

What will be asked of you if you take part in this clinical trial?

graphic

Step 1: Screening

At your first visit(s), you will:

  • Meet the clinical trial doctor and team at the location of the trial. This may be different from where you have received treatment in the past.
  • Review and sign an informed consent to join the DeLLphi-306 clinical trial.
  • Complete a general health assessment, including a physical exam, medical history, blood tests, and imaging.
  • Have your tumor sampled.*

*This may not be needed in all cases. Your doctor will let you know if this is not needed.

If you meet the requirements and decide to join this clinical trial, you will move on to Step 2.

graphic

Step 2: Treatment

Approximately 400 participants will be randomly assigned to receive either tarlatamab (investigational drug) or placebo.

The tarlatamab group will:

  • Receive tarlatamab by infusion (in a vein) once a week for the first 3 weeks and then once every 2 weeks afterwards in a 28-day cycle.
  • Attend clinical trial appointments and check-ups to record your progress.

The placebo group will:

  • Receive a placebo by infusion (in a vein) once a week for the first 3 weeks and then once every 2 weeks afterwards in a 28-day cycle.
  • Attend clinical trial appointments and check-ups to record your progress.
graphic

Step 3: End of treatment

You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. The treatment you receive in this trial or your participation in this clinical trial may end if:

  1. Your cancer gets worse.
  2. You experience serious side-effects from treatment.
  3. You decide to stop the trial at any time.

The clinical trial team will schedule a follow-up visit with you approximately 9 weeks after your last trial treatment.

graphic

Step 4: Long term follow-up (up to 4 years)

The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 6 months.

Clinical Trial Locations

If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.

phone graphic

Where can I get more information?

To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.

AmgenMedInfo.com

866-572-6436

Monday - Friday 8am to 8pm (ET)

Contact Amgen